Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620256 · ClinicalTrials.gov registry record · Phase 2
Adjunctive Study of AL-37807 Ophthalmic Suspension
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT00620256 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 129 participants.
The verdict
NCT00620256, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and intraocular pressure-lowering efficacy of AL-37807 ophthalmic suspension vs. Timolol gel forming solution vs. AL-37807 vehicle, all dosed concomitantly with Xalatan, in patients with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Latanoprost ophthalmic solution
- DRUG AL-37807 ophthalmic suspension, 0.1%
- DRUG Timolol gel forming solution, 0.5%
- OTHER AL-37807 ophthalmic solution vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620256
The ClinicalTrials.gov registry entry for NCT00620256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Latanoprost ophthalmic solution is the first listed.
NCT00620256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620256 about?
NCT00620256 is a clinical study titled "Adjunctive Study of AL-37807 Ophthalmic Suspension". The purpose of the study is to compare the safety and intraocular pressure-lowering efficacy of AL-37807 ophthalmic suspension vs. Timolol gel forming solution vs. AL-37807 vehicle, all dosed concomitantly with Xalatan, in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00620256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2007-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00620256?
The interventions under investigation include: Latanoprost ophthalmic solution (DRUG), AL-37807 ophthalmic suspension, 0.1% (DRUG), Timolol gel forming solution, 0.5% (DRUG), AL-37807 ophthalmic solution vehicle (OTHER).
Who is sponsoring clinical trial NCT00620256?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.